COVID-19 Updates | Another Indian Firm Gets Approval for Trials of Potential COVID-19 Drug
- 3 years ago
Indian pharmaceutical Strides Pharma Science has received regulatory approval to start clinical trials of antiviral drug favipiravir, which has been touted as a potential treatment for COVID-19. The company has received approval from the Drug Controller General of India to conduct human studies of favipiravir in the country. Favipiravir is manufactured under the brand name Avigan by a unit of Japan’s Fujifilm Holdings. Earlier this month, Glenmark Pharmaceuticals became the first pharma company in India to get the nod to conduct trials on the drug. The results of this study are expected by July or August.
Like our work? Click here to support The Wire: https://thewire.in/support
The founding premise of The Wire is this: if good journalism is to survive and thrive, it can only do so by being both editorially and financially independent. This means relying principally on contributions from readers and concerned citizens who have no interest other than to sustain a space for quality journalism. As a publication, The Wire will be firmly committed to the public interest and democratic values.
We publish in four different languages!
For English, visit www.thewire.in
for Hindi: http://thewirehindi.com/
for Urdu: http://thewireurdu.com
for Marathi: https://marathi.thewire.in
If you are a young writer or a creator, you can submit articles, essays, photos, poetry – anything that’s straight out of your imagination – to LiveWire, The Wire’s portal for the young, by the young. https://livewire.thewire.in/
You can also follow The Wire’s social media platforms and engage with us.
Facebook
https://www.facebook.com/TheWire/
https://www.facebook.com/TheWireHindi/
https://www.facebook.com/TheWireUrdu/
https://www.facebook.com/TheWireMarathi/
Twitter
https://twitter.com/thewire_in
https://twitter.com/thewirehindi
https://twitter.com/TheWireUrdu
https://twitter.com/TheWireMarathi
https://twitter.com/livewire
Instagram
https://www.instagram.com/thewirein/
https://www.instagram.com/livewirein/
Don’t forget to hit the subscribe button to never miss a video from The Wire!
Like our work? Click here to support The Wire: https://thewire.in/support
The founding premise of The Wire is this: if good journalism is to survive and thrive, it can only do so by being both editorially and financially independent. This means relying principally on contributions from readers and concerned citizens who have no interest other than to sustain a space for quality journalism. As a publication, The Wire will be firmly committed to the public interest and democratic values.
We publish in four different languages!
For English, visit www.thewire.in
for Hindi: http://thewirehindi.com/
for Urdu: http://thewireurdu.com
for Marathi: https://marathi.thewire.in
If you are a young writer or a creator, you can submit articles, essays, photos, poetry – anything that’s straight out of your imagination – to LiveWire, The Wire’s portal for the young, by the young. https://livewire.thewire.in/
You can also follow The Wire’s social media platforms and engage with us.
https://www.facebook.com/TheWire/
https://www.facebook.com/TheWireHindi/
https://www.facebook.com/TheWireUrdu/
https://www.facebook.com/TheWireMarathi/
https://twitter.com/thewire_in
https://twitter.com/thewirehindi
https://twitter.com/TheWireUrdu
https://twitter.com/TheWireMarathi
https://twitter.com/livewire
https://www.instagram.com/thewirein/
https://www.instagram.com/livewirein/
Don’t forget to hit the subscribe button to never miss a video from The Wire!